NCT04910685 2026-03-10
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
Blueprint Medicines Corporation
Cogent Biosciences, Inc.